Profile data is unavailable for this security.
About the company
Devyser Diagnostics AB is a Sweden-based company engaged in development, manufacture ad sale of kits for genetic testing in routing diagnostic to laboratories. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The company has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The Company provides its products in more than 45 countries.
- Revenue in SEK (TTM)198.00m
- Net income in SEK-71.40m
- Incorporated2004
- Employees119.00
- LocationDevyser Diagnostics ABInstrumentvagen 19HAGERSTEN 126 53SwedenSWE
- Phone+46 856215850
- Websitehttps://www.devyser.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diamyd Medical AB | 130.00k | -151.85m | 1.30bn | 27.00 | -- | 8.77 | -- | 9,985.54 | -1.60 | -1.60 | 0.0014 | 1.46 | 0.0006 | -- | 3.17 | 4,814.82 | -71.82 | -34.32 | -83.67 | -38.45 | -10,161.54 | -3,111.20 | -116,806.90 | -17,499.13 | -- | -- | 0.1737 | -- | -76.19 | -39.23 | -30.82 | -- | -- | -- |
| Cereno Scientific AB | 0.00 | -69.48m | 1.39bn | 5.00 | -- | 5.49 | -- | -- | -0.283 | -0.283 | 0.00 | 0.8998 | 0.00 | -- | -- | 0.00 | -23.45 | -16.81 | -25.41 | -18.26 | -- | -- | -- | -- | -- | -9.44 | 0.1519 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
| Solar Foods Oyj | 200.52k | -123.76m | 1.43bn | 40.00 | -- | 4.36 | -- | 7,113.47 | -0.4438 | -0.4438 | 0.0007 | 1.15 | 0.0004 | -- | 0.0049 | 558.71 | -21.32 | -- | -24.11 | -- | 20,183.14 | -- | -61,719.29 | -- | -- | -2.71 | 0.4266 | -- | -- | -- | -66.44 | -- | -- | -- |
| Nightingale Health Oyj | 50.45m | -202.17m | 1.43bn | 86.00 | -- | 2.23 | -- | 28.29 | -0.2895 | -0.2895 | 0.0722 | 1.37 | 0.0441 | 2.33 | 3.46 | 50,674.42 | -17.67 | -14.59 | -18.99 | -15.99 | 66.45 | 77.90 | -400.71 | -435.73 | 9.74 | -- | 0.0308 | -- | 4.21 | 16.13 | 3.43 | -- | 8.54 | -- |
| XSpray Pharma AB (publ) | 0.00 | -258.05m | 1.60bn | 24.00 | -- | 2.52 | -- | -- | -7.81 | -7.81 | 0.00 | 17.14 | 0.00 | -- | -- | 0.00 | -37.64 | -18.38 | -40.48 | -19.26 | -- | -- | -- | -- | 1.51 | -- | 0.0543 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Vicore Pharma Holding AB | 104.24m | -196.45m | 1.88bn | 29.00 | -- | 2.37 | -- | 18.05 | -1.72 | -1.72 | 0.9135 | 3.38 | 0.2045 | -- | 43.73 | 4,343,459.00 | -38.54 | -58.65 | -41.49 | -65.58 | -- | -- | -188.45 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
| Egetis Therapeutics AB (publ) | 79.20m | -295.80m | 1.94bn | 33.00 | -- | 4.96 | -- | 24.49 | -1.07 | -1.07 | 0.2882 | 1.09 | 0.1425 | 23.00 | 3.61 | 2,933,333.00 | -48.67 | -33.02 | -61.23 | -36.46 | 85.48 | -- | -341.54 | -357.72 | 0.9808 | -19.71 | 0.2605 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| Hansa Biopharma AB | 189.39m | -654.78m | 2.05bn | 135.00 | -- | -- | -- | 10.82 | -11.34 | -11.34 | 3.21 | -4.72 | 0.1794 | 34.61 | 1.25 | 1,127,321.00 | -62.01 | -47.96 | -86.68 | -56.12 | 53.43 | 64.18 | -345.73 | -835.04 | 2.44 | -41.44 | 1.50 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
| Devyser Diagnostics AB | 198.00m | -71.40m | 2.28bn | 119.00 | -- | 6.52 | -- | 11.51 | -4.37 | -4.37 | 12.12 | 21.17 | 0.4019 | 1.97 | 5.29 | 1,677,966.00 | -14.51 | -8.97 | -16.40 | -10.15 | 80.00 | 80.14 | -36.11 | -23.91 | 3.81 | -- | 0.1492 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
| BioInvent International AB | 38.64m | -409.65m | 3.13bn | 115.00 | -- | 3.12 | -- | 81.07 | -6.23 | -6.23 | 0.5871 | 15.24 | 0.0301 | -- | 0.6849 | 348,072.10 | -31.87 | -17.50 | -33.70 | -18.64 | -- | -- | -1,060.29 | -131.63 | 13.16 | -- | 0.0167 | -- | -78.09 | 13.14 | -677.13 | -- | 28.17 | -- |
Data as of Nov 13 2024. Currency figures normalised to Devyser Diagnostics AB's reporting currency: Swedish Krona SEK
27.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 30 Jun 2023 | 1.10m | 6.70% |
| Swedbank Robur Fonder ABas of 30 Sep 2024 | 1.07m | 6.49% |
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 30 Jun 2023 | 987.75k | 5.99% |
| Deka Investment GmbHas of 30 Apr 2024 | 420.20k | 2.55% |
| Wahlstedt & Partners ABas of 30 Sep 2024 | 362.26k | 2.20% |
| Fondita Fund Management Co. Ltd.as of 30 Sep 2024 | 175.00k | 1.06% |
| Aktia Bank Plc (Investment Management)as of 30 Sep 2024 | 170.00k | 1.03% |
| E. �hman J :or Fonder ABas of 31 May 2024 | 138.55k | 0.84% |
| Cicero Fonder ABas of 30 Sep 2024 | 64.95k | 0.39% |
| Barius Capital Management GmbHas of 28 Jun 2024 | 61.43k | 0.37% |
More ▼
Data from 28 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
